MannKind Corporation (NASDAQ: MNKD)
MannKind is a company that has struggled for quite some time at this point. Unfortunately, while the company does have a great product, sales surrounding that product have been overwhelmingly poor. Nonetheless, the company will be holding a conference call for investors, and chances are that the call will lead to a strong week. Today, we’ll talk about when the call will be held, what I’m expecting to hear on the call, and what I expect to see from MNKD moving forward. So, let’s get right to it…
Trade smarter and make more money with Tradespoon!
MNKD Will Be Hosting An Analyst Call
As mentioned above, MannKind will be hosting an analyst call for the investment community relatively soon. The call is scheduled for tomorrow, April 18th, at 5:00 PM eastern time. To participate in the call, you can call toll free at (888) 224-7957 or on the local line at (303) 223-4394. When you call in, make sure to have the participant code (21809665) handy, as you will need it. You can also watch the presentation live at www.mannkindcorp.com.
What I’m Expecting To Hear On The Call
As mentioned above, MNKD is a company that has an absolutely incredible product. The product is known as Afrezza Inhalation Powder and is the first approved insulin that is inhaled rather than injected. However, sales on the product were incredibly poor throughout the first year after MNKD contracted with Sanofi, a competing company, for the commercialization of the treatment. Nonetheless, it has been announced that the call will be centered around plans with regard to Afrezza Inhalation Powder. Here’s what I’m expecting to hear:
- Commercialization Partners – In a statement made in January, MNKD announced that once it received full commercialization rights back from Sanofi, it would be looking to start new commercialization relationships to push Afrezza sales upward. I’m expecting that we will hear about the effort to start these relationships on this call and, if we’re lucky, we’ll hear that MannKind has already found a partner.
- Specialized Diabetes Care Centers – Another big statement made by MannKind in January was the announcement that the company would be teaming up with independent Specialized Diabetes Care Centers. MNKD gave the care centers the rights to use the Afrezza name in branding, marketing, and other efforts. In exchange, Specialized Diabetes Care Centers will be treating diabetes in real time with Afrezza. I’m expecting that we will hear more about this relationship on the call and when this relationship will be starting.
- Other Commercialization Efforts – The truth is that after signing Afrezza commercialization rights off to Sanofi in late 2014, MNKD hasn’t been able to do much with the treatment. However, the rights have been transferred back to MannKind in full, and now is the time for the company to shine. So, I’m expecting to hear quite a bit more about commercialization efforts that the company has held under wraps until the transfer of rights was complete.
What We Can Expect To See From MNKD Moving Forward
At this point, I have a very bullish expectation of what we can expect to see from MannKind. The reality is that the company’s stock has been dragged through the dirt thanks to the misdirection of Sanofi. Nonetheless, MNKD now has full rights to Afrezza again, and I believe that their commercialization efforts will push the stock to the next level. All in all, I have overwhelmingly high hopes for the stock.
Don’t waste your time! Click here to find winning trades in minutes!
What Do You Think?
Where do you think MNKD is headed moving forward and why? Let us know your opinion in the comments below!
[Image Courtesy of Wikipedia]